{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970128",
  "id": "02970128",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250717",
  "time": "0945",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lwctb2xwyxmj.pdf",
  "summary": "- **Trial Completion**: Enrollment completed for Co-PSMA trial (Phase II) evaluating 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 in prostate cancer recurrence detection.  \n- **Upcoming Catalysts**: Results expected \"in the coming months\"; Phase III trials (CLARIFY and AMPLIFY) progressing, with AMPLIFY recruitment opening shortly.  \n- **Previous Data**: Positive results from PROPELLER and COBRA trials support 64Cu-SAR-bisPSMA's diagnostic advantages (higher sensitivity, delayed imaging flexibility).  \n\n*No material financial, capital structure, or trading-specific updates identified.*",
  "usage": {
    "prompt_tokens": 2259,
    "completion_tokens": 136,
    "total_tokens": 2395,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T23:52:11.091224"
}